BioVentix PLC Director/PDMR Shareholding (3901X)

TIDMBVXP

RNS Number : 3901X

BioVentix PLC

25 April 2023

Bioventix plc

("Bioventix" or "the Company")

Director Dealing

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified on 24 April 2023 that on 24 April 2023 Bruce Hiscock, Chief Financial Officer of the Company, purchased a total of 11 ordinary shares of 5 pence each in the Company ("Ordinary Shares"), at an average price of 3,823 pence per Ordinary Share (the "Purchase"). The Ordinary Shares were purchased under a dividend reinvestment plan ("DRIP").

Following the Purchase, Bruce Hiscock has a beneficial interest in 761 Ordinary Shares, representing approximately 0.01 per cent. of the issued share capital of the Company.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.

For further information please contact:

 
 Bioventix plc                                         Tel: 01252 728 001 
  Peter Harrison             Chief Executive Officer 
 
 finnCap Ltd                                           Tel: 020 7220 0500 
  Geoff Nash/Simon Hicks     Corporate Finance 
  Alice Lane                 ECM

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                             Bruce Hiscock 
     -------------------------------  ---------------------------------- 
 2.   Reason for the Notification 
     ------------------------------------------------------------------- 
 a)   Position/status                  Chief Financial Officer 
     -------------------------------  ---------------------------------- 
 b)   Initial notification/Amendment   Initial notification 
     -------------------------------  ---------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------- 
 a)   Name                             Bioventix Plc 
     -------------------------------  ---------------------------------- 
 b)   LEI                              213800225MHX7LZQY108 
     -------------------------------  ---------------------------------- 
 4.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ------------------------------------------------------------------- 
 a)   Description of the               Ordinary Shares of 5 pence each 
       Financial instrument, 
       type of instrument 
      Identification code              GB00B4QVDF07 
     -------------------------------  ---------------------------------- 
 b)   Nature of the transaction        Purchase of Ordinary Shares 
     -------------------------------  ---------------------------------- 
 c)   Price(s) and volume(s)           11 Ordinary Shares 
                                        3,823 pence 
     -------------------------------  ---------------------------------- 
 d)   Aggregated information:          Purchase of 11 Ordinary Shares at 
                                        3,823 pence each 
        *    Aggregated volume 
 
 
 
        *    Price 
     -------------------------------  ---------------------------------- 
 e)   Date of the transaction          24 April 2023 
     -------------------------------  ---------------------------------- 
 f)   Place of the transaction         London Stock Exchange, AIM Market 
                                        (XLON) 
     -------------------------------  ----------------------------------

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHEANLSADLDEEA

(END) Dow Jones Newswires

April 25, 2023 05:35 ET (09:35 GMT)

Bioventix (AQSE:BVXP.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024